In this episode of the CEOLIVE.TV Investor profile series we speak with CEO, Peter Bloch and the Co-Founder and Operating Officer, Michal Prywata of Bionik Laboratories, Corp.
Bionik Laboratories (BNKL) is a pioneering global medical device and robotics company focused on providing rehabilitation solutions to individuals with neurological disorders.
They have a pipeline of commercial and development stage robotic products addressing both upper and lower body rehabilitation.
Their recent acquisition of Interactive Motion Technologies adds 3 commercial stage products to their portfolio.
In 2015 they reported revenues of $2 million with significant opportunity for growth in the near term.
Bionik Laboratories has a pioneering team responsible for foundational patents in robotics and their growth strategy is focused on developing earlier stage programs through to commercialization and acquiring licensing synergistic products and technologies.
Bionik has just announced the completion of a landmark study marking the largest trial conducted to date in robotic rehabilitation. The Robot Assisted Training for the Upper Limb after Stroke study has achieved 50% enrollment into a multicenter, randomized controlled research trial to evaluate the clinical and cost effectiveness of robot-assisted training in post-stroke care.
The study was funded by the NIHR Health Technology Assessment Program conducted throughout the United Kingdom and employs the Bionik Laboratories InMotion Upper Extremity Robotic Gym.
The completion of enrollment of the 720 stroke patients is expected before the end of 2018 with results to be published in 2019.
Dr. Hermano Krebs, Chief Science Officer of Bionik added, “We are thrilled to be a part of this landmark study, the largest of its kind to date. The RATULS research of robot-assisted therapy is important in the clinical development of the Bionik product pipeline as we aim to offer the best rehabilitation therapies for those affected by neurological disorders. For patients who suffer from a stroke, it is reported that 85% of those patients experience some loss in the ability to use the arm and hand. We believe that the InMotion systems offer people an effective opportunity for therapy to address the decrease in function they experience.”
Based on their world class scientific team, cutting edge product pipeline and their recent acquisition of Interactive Motion Technologies we believe Bionik Laboratories is positioned itself as a leading robotics and medical device company and therefore worth keeping an eye on over the coming quarters.
This has been a Video News Release featuring Bionik Laboratories., a pioneering global medical device and robotics company focused on providing rehabilitation solutions to individuals with neurological disorders.
Bionik trades under ticker BNKL and you can find out more about them by visiting www.bioniklabs.com.
Forward Looking Statements
This CEOLIVE.TV video contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company’s contracts, the Company’s ability to raise sufficient development and working capital, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.